STL Index for: Maxwell B Sauder

Discover how zasocitinib, a next-generation selective TYK2 inhibitor, may redefine psoriasis treatment with targeted efficacy, reduced off-target JAK effects, and promising late-stage clinical results.

Health Canada approved selumetinib in 2022 for treating inoperable plexiform neurofibromas in children with neurofibromatosis type 1. Clinical trials showed 74% of patients experienced significant tumor shrinkage, with improvements in pain and quality of life. The oral MEK inhibitor offers the first targeted therapy for these historically difficult-to-treat nerve tumors.

Breast and prostate cancer patients frequently use hormonal therapy to improve treatment outcomes and survival. However, these medications can be associated with numerous dermatologic adverse effects.

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

The CaSMO (Canadian Skin Management in Oncology) algorithm focuses on general skincare measures to prevent or reduce the severity of cancer-treatment-related cutaneous toxicities.